NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Medical Instruments & Supplies · USD

Nephros, Inc. (NEPH) Stock Analysis

Nephros, Inc. (NEPH) is a Medical Instruments & Supplies stock listed on NASDAQ and quoted in US Dollar.

NEPH

$4.06

−$0.12 (−2.87%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare NEPH with… →

NEPH Key Statistics

As of Sep 4, 2026
Trading
Open
$4.15
Previous Close
$4.18
Day's Range
4.06–4.26
52-Week Range
2.66–6.42
Volume
17.90K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.56
Valuation
Market Cap
$44.09M
P/E Ratio
25.38
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
19.33
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.13
EPS (ttm)Profit attributable to each share over the last twelve months.
0.16
Financials (FY)
Revenue (FY)
$18.79M+32.67%
Net Income (FY)
$1.19M+1513.51%
Profit marginThe share of revenue left as profit after all costs and taxes.
8.38%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
10.86M
1-Year Return
+1.50%
Dividend and dates
Earnings Date
November 5, 2026
Avg Volume
19.15K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

NEPH Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−16.80%
2025+231.97%
2024−57.51%
2023+198.28%
2022−80.34%
2021−31.24%
2020−13.77%
2019+93.96%
2018+26.67%
2017+21.62%
2016 (partial year)+27.59%

As of September 4, 2026.

NEPH Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$18.79M$1.19M6.4%
2024$14.16M$74.00K0.5%
2023$14.24M−$1.58M−11.1%
2022$9.98M−$7.38M−74.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$18.79M$11.63M$1.15M$1.19M6.4%
2024$14.16M$8.72M$6.00K$74.00K0.5%
2023$14.24M$8.41M−$1.59M−$1.58M−11.1%
2022$9.98M$4.73M−$4.34M−$7.38M−74.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

NEPH Valuation vs Medical Instruments & Supplies Median

Median of 55 stocks
MetricNEPHMedical Instruments & Supplies medianvs median
P/E25.3835.6129% below
P/S ratio2.133.1733% below
Profit margin8.38%0.85%7.5 pts above

Medians across 55 Medical Instruments & Supplies stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Nephros, Inc. (NEPH) at $44.09M. The company sits in the Healthcare sector, in the Medical Instruments & Supplies industry. The company reports 36 employees.

The 52-week range on file runs from $2.66 to $6.42. NEPH last closed at $4.06 on September 4, 2026. That is −$0.12 (−2.87%) against the previous close. The latest close sits 52.63% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $18.79M. That is +32.67% against the prior fiscal year, when revenue was $14.16M. Net income for the same year was $1.19M. That is +1,513.51% against the prior fiscal year. The reported profit margin is 8.38%. That is 7.5 percentage points above the Medical Instruments & Supplies median of 0.85%. Earnings per share on a trailing basis come to 0.16.

Across the 4 fiscal years on file, revenue moves from $9.98M in 2022 to $18.79M in 2025. Of those 4 years, 2 report positive net income.

Valuation Assessment

NEPH trades at a trailing price-to-earnings ratio of 25.38. That is 28.74% below the Medical Instruments & Supplies median of 35.61. The forward P/E on file is 19.33. The price-to-sales ratio is 2.13. On price-to-sales that is 32.94% below the Medical Instruments & Supplies median of 3.17. 55 Medical Instruments & Supplies companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is +1.50%. Measured over 10 years, that is −1.41% a year compounded. Beta against the wider market is reported at 1.56. Annualized volatility over the trailing 10 years is 84.11%.

Growth & Income

The record shows no dividend for NEPH.

Across the complete calendar years on file, 2025 returned +231.97% and 2022 returned −80.34%. Of the 9 complete calendar years on file, 5 finished higher. So far in 2026 the price is −16.80%.

Peer Comparison

Nephros, Inc. (NEPH) operates in the Medical Instruments & Supplies industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Nephros, Inc. NEPH $44.09M 25.4
Intuitive Surgical, Inc. ISRG $131.38B 42.4
Becton, Dickinson and Company BDX $50.32B 32.0
Medline Inc. MDLN $49.23B 45.7

The Medical Instruments & Supplies industry average P/E ratio is 35.6x. Nephros, Inc. trades at a P/E of 25.4.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Instruments & Supplies Stocks

ISRG

Intuitive Surgical, Inc.

$131.38B

 BDX

Becton, Dickinson and Company

$50.32B

 MDLN

Medline Inc.

$49.23B

 ALC

Alcon Inc.

$34.08B

 RMD

ResMed Inc.

$32.94B

 WST

West Pharmaceutical Services, Inc.

$23.93B
View all Medical Instruments & Supplies stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Nephros, Inc.

Nephros, Inc., a commercial-stage company, develops and sells water filtration solutions for medical and commercial applications in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in foodservice and hospitality, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water; reduce biofilm and scale build-up; and remove cysts, particulates, and lead from water systems. It markets its products to food service and hospitality sectors including quick-service restaurants, convenience stores, and restaurants. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.

Visit website →